You have access
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition
Matthew J. Fell, Christian Mirescu, Kallol Basu, Boonlert Cheewatrakoolpong, Duane E. DeMong, J. Michael Ellis, Lynn A. Hyde, Yinghui Lin, Carrie G. Markgraf, Hong Mei, Michael Miller, Frederique M. Poulet, Jack D. Scott, Michelle D. Smith, Zhizhang Yin, Xiaoping Zhou, Eric M. Parker, Matthew E. Kennedy and John A. Morrow
Journal of Pharmacology and Experimental Therapeutics December 2015, 355 (3) 397-409; DOI: https://doi.org/10.1124/jpet.115.227587